CatalystMarker
← board

AWHL

distress 8/10 · high distress / dilution risk
$0.400%today-42% from 52w high
aspirawh.com36 employeesFounded 1993Austin, TXDiagnostics & Research
Revenue
pre-revenue
Liquidity
$1M
Runway
0.3 yrs
Shares 1y
+22%

Price & events

-11.1% over 6M
$0.27$0.41$0.54Jan 26Apr 26Jul 26315kfinancing: 8-K material_agreement (2026-07-15)financing: 8-K private_placement (2026-06-09)financing: 8-K material_agreement (2026-05-26)financing: 8-K material_agreement (2026-01-30)
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+2.6%
1W
-13.0%
1M
+0.0%
3M
-11.1%
6M
+90.5%
1Y
-74.0%
2Y
-99.5%
5Y
-99.6%
All

Overview

Market Cap
$17.40M
Enterprise Value
$17.04M
Volume
15.00K
52 Week Range
$0.18 – $0.69
Total Shares
43.50M
Float Shares
36.48M
Short %
0.79%
% Held by Insiders
12.71%
% Held by Institutions
0.87%
RVOL
0.54x
Beta
1.99

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 4

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 43,500,411 · 2 offerings/1y · 4 PIPEs
  • 2026-07-158-Kmaterial_agreement
  • 2026-06-098-Kprivate_placement
  • 2026-05-268-Kmaterial_agreement
  • 2026-01-308-Kmaterial_agreement
  • 2026-01-12424B3offering
  • 2026-01-09EFFECTshelf_effective
  • 2025-12-31S-1shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.